Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest update is out from Oncimmune Holdings ( (GB:ONC) ).
Oncimmune Holdings plc has announced the Notice of its Annual General Meeting (AGM) for 2025, scheduled for February 27th in London. The company is in the process of finalizing its financial results for the fiscal year ending August 2024, with an expectation to publish its annual report by the end of February 2025. This announcement underscores Oncimmune’s routine financial and operational activities, supporting its market position in precision medicine and ongoing collaborations with stakeholders in the pharmaceutical and biotechnology sectors.
More about Oncimmune Holdings
Oncimmune Holdings plc is a precision medicine company specializing in autoantibody profiling within the pharmaceutical and biotechnology industries. The company focuses on discovering novel biomarkers and drug targets to enable precision medicine, partnering with global pharmaceutical companies and contract research organizations to develop targeted therapies for immune-mediated diseases. Headquartered in the UK, Oncimmune operates a discovery and development facility in Dortmund, Germany, and maintains business development teams in the US and Europe.
YTD Price Performance: -29.62%
Average Trading Volume: 235,984
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £11.29M
For detailed information about ONC stock, go to TipRanks’ Stock Analysis page.
